How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about sacituzumab govitecan

Marketing authorisation indication

2.1 Sacituzumab govitecan (Trodelvy, Gilead Sciences) has a marketing authorisation for 'the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior lines of systemic therapies, at least one of them given for unresectable locally advanced or metastatic disease'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for sacituzumab govitecan.

Price

2.3 The list price of sacituzumab govitecan is £793.00 per 180 mg vial (excluding VAT; BNF online accessed March 2022).

2.4 The company has a commercial arrangement, which would have applied if the technology had been recommended.